Paul Oberstein, MD
Enriched profileDirector, Gastrointestinal Medical Oncology, Perlmutter Cancer Center; Associate Professor of Medicine · NYU Langone Health
Paul Oberstein is Director, Gastrointestinal Medical Oncology, Perlmutter Cancer Center; Associate Professor of Medicine at NYU Langone Health. OpenAlex indexes 231 publications with 7,792 citations (h-index 25); ClinicalTrials.gov lists 6 registered studies with this person as an investigator.
Data verified 17 Oct 2026
Overview
Updated 18 Oct 2026
Paul Oberstein, MD, is Director, Gastrointestinal Medical Oncology, Perlmutter Cancer Center at NYU Langone Health (Perlmutter Cancer Center). The public record shows 231 publications with 7,792 citations (h-index 25), centered on Pancreatic and Hepatic Oncology Research, Cancer Immunotherapy and Biomarkers, Pancreatitis Pathology and Treatment. It also documents an investigator role on 6 registered clinical trials, industry payments reported by 15 companies.
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Pancreatic and Hepatic Oncology Research
- 6 registered trials on ClinicalTrials.gov
- Open Payments reporting from 15 companies
Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 21 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 48.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 18 Oct 2026
Listed as an investigator on 6 registered studies on ClinicalTrials.gov. The most recent:
Industry payments
Updated 18 Oct 2026
15 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Ipsen Biopharmaceuticals, IncProgram year202513 payments$32,789openpaymentsdata.cms.gov ↗
- JAZZ PHARMACEUTICALS INC.Program year202516 payments$28,830openpaymentsdata.cms.gov ↗
- Janssen Scientific Affairs, LLCProgram year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
75.3%Antidiarrheal microorganisms40.3%Creon100%Part D≥13 patientsSerotonin-3 Receptor Antagonist35.1%Ondansetron Hcl100%Part D≥23 patientsNervous system
24.7%Phenothiazine24.7%Prochlorperazine Maleate100%Part D≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 18 Oct 2026
60 congress contributions (2013–2026) across AACR, ASCO, ASTRO per OpenAlex. The most recent:
- Circulating tumor DNA monitoring in peptide receptor radionuclide therapy–treated patients with gastroenteropancreatic neuroendocrine tumors.
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 18 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial.
Nature medicine
Clinical Trial2026 - Emerging Therapeutic Approaches to Pancreatic Adenocarcinoma: Advances and Future Directions.
Current treatment options in oncology
Review2025
Most-cited works
by citation count (OpenAlex)- 01Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal AdenocarcinomaArticle2,070 citations2014
- 02Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort studyArticle1,733 citations2020
- 03
- 04
- 05
Network
Updated 18 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 18 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Other
nyulangone.org/doctors/1265686075/paul-e-oberstein
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyulangone.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 18 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
The Ohio State University College of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyulangone.org ↗ - MS in Biostatistics
Mailman School of Public Health, Columbia University
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyulangone.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyulangone.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyulangone.org ↗
Secondary affiliations
appointments beyond the home institution- Assistant Director
Pancreatic Cancer Center, NYU Langone Health
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyulangone.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nyulangone.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Gareth Morgan, MD
NYU Langone Health
Nathan Levin, MD
NYU Langone Health
Ira Jacobson, MD
NYU Langone Health
Michael Zelefsky, MD
NYU Langone Health
Eric Van Cutsem, MD, PhD
University Hospitals Leuven (UZ Leuven)
Josep Tabernero, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Charles Fuchs, MD, MPH
Tubulis GmbH